Kidney Cancer Journal 127
Volume 16, Number 1
• Revisiting the VHL Con-
nection: How a Common
Pathway Now More Closely
Links Sporadic RCC, VHL-
Associated Syndromes
• The Classification and
Treatment of Non-Clear Cell
Renal Cell Carcinoma
• Late Relapsing Renal Cell Carcinoma: A Brief Review
Suggests Expected PFS and OS 5 Years and Beyond After
Nephrectomy
Volume 16, Number 2
• Optimizing Benefit and Limiting
Immune-Related Adverse
Effects Following Checkpoint
Inhibitor Blockade
• ASCO 2018: Highlights From
the Meeting Through the
Lens of a Key Opinion Leader
• Controversies and Consensus
Surrounding Initial Cytoreductive
Nephrectomy vs
Targeted Therapy: What is the
Optimal Approach?
Volume 16, Number 3
• Combination Immunotherapy
and Targeted Therapy:
Will New Combinations Raise
the Tail of the Survival
Curve?
• Evolving Role of TKI
Monotherapy in Front Line
Metastatic Clear Cell RCC
• The Landscape of Adjuvant
Therapy: A Controversy in
Search of a Consensus
Volume 16, Number 4
• Active Surveillance in Kidney
Cancer: An Update on
Current Guidelines
• Meeting Report: Highlights
from the 2018 ESMO and
International Kidney Cancer
Symposium Sessions
2 0 1 8 I N D E X
Carcinoma Database Consortium (IMDC) model. Although
recent studies are still emerging from the hypothesis-generating
stage, molecular and genomic alterations are likely to
be integrated into such prognostic models in the near future.
Precision medicine and next generation sequencing are the
increasingly used buzzwords to describe innovative strategies
to deliver the right treatment to the right patient at the right
time. As emerging data unravel more of the molecular underpinnings
of RCC, the focus has turned toward tumor suppressor
genes and the pivotal roles they play in determining
outcomes. We are likely to see a broad impact on clinical
trial design as these approaches update the paradigm of treatment
in the immune-oncology era.
Within the last 5 years, particularly, emerging data have
more clearly pointed toward potential strategies with translational
impact as more studies target the genetic basis of a
significant percentage of familial RCC that has remained unknown.
There is precedent for genes mutated in the germline
(such as VHL) that are also mutated in the sporadic setting.
Consequently, somatically mutated genes may explain familial
RCC if mutated in the germline. For a more detailed
analysis of these trends, please review the content of this
issue to keep current with critical reading on precision medicine.
So, what is the answer to the question posed in the headline:
Is Precision Medicine the Wave of the Future or a Cautionary
Tale? It looks like a bit of both. Stay tuned.
Robert A. Figlin, MD
Editor-in-Chief
EDITOR’S MEMO
(continued from page 103)